- Home
- CPAC vs ATXS Comparison
CPAC vs ATXS Comparison
Compare CPAC & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CPAC
- ATXS
- Stock Information
- Founded
- CPAC 1949
- ATXS 2008
- Country
- CPAC Peru
- ATXS United States
- Employees
- CPAC N/A
- ATXS N/A
- Industry
- CPAC Building Materials
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- CPAC Industrials
- ATXS Health Care
- Exchange
- CPAC Nasdaq
- ATXS Nasdaq
- Market Cap
- CPAC 495.3M
- ATXS 584.1M
- IPO Year
- CPAC 2012
- ATXS 2015
- Fundamental
- Price
- CPAC $5.91
- ATXS $9.55
- Analyst Decision
- CPAC Sell
- ATXS Strong Buy
- Analyst Count
- CPAC 1
- ATXS 5
- Target Price
- CPAC $6.00
- ATXS $28.00
- AVG Volume (30 Days)
- CPAC 15.2K
- ATXS 340.4K
- Earning Date
- CPAC 10-29-2024
- ATXS 11-13-2024
- Dividend Yield
- CPAC 8.96%
- ATXS N/A
- EPS Growth
- CPAC 7.38
- ATXS N/A
- EPS
- CPAC 0.12
- ATXS N/A
- Revenue
- CPAC $527,798,215.00
- ATXS N/A
- Revenue This Year
- CPAC N/A
- ATXS N/A
- Revenue Next Year
- CPAC N/A
- ATXS N/A
- P/E Ratio
- CPAC $10.04
- ATXS N/A
- Revenue Growth
- CPAC N/A
- ATXS N/A
- 52 Week Low
- CPAC $4.82
- ATXS $5.88
- 52 Week High
- CPAC $6.65
- ATXS $16.90
- Technical
- Relative Strength Index (RSI)
- CPAC 47.57
- ATXS 41.21
- Support Level
- CPAC $5.80
- ATXS $9.40
- Resistance Level
- CPAC $6.10
- ATXS $9.99
- Average True Range (ATR)
- CPAC 0.16
- ATXS 0.58
- MACD
- CPAC 0.02
- ATXS -0.01
- Stochastic Oscillator
- CPAC 58.70
- ATXS 9.32
About CPAC Cementos Pacasmayo S.A.A. (Each representing five)
Cementos Pacasmayo SAA is a Peruvian cement company that primarily produces, distributes, and sells cement and cement-related materials, such as concrete blocks and ready-mix concrete. The company's products are primarily used in construction. It also produces and sells quicklime for use in mining operations. The company sells its products mainly in the northern part of Peru. It owns three cement production facilities. Its flagship Pacasmayo facility is located in the northwest region of Peru, while its new cement plant in Piura and smaller Rioja facility are located in the northeast region of Peru.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.